An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: A case series

Paul, Joan; Foss, Clare E.; Hirano, Stefanie A.; Cunningham, Tina D.; Pariser, David M.

doi:10.1016/j.jaad.2012.07.014

Cited by 47 publications

(39 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One of these 10 patients had oral involvement which improved significantly by the end of the study. 8 Apremilast appears to be safe as a long term treatment. There were no serious adverse effects reported in large studies of apremilast when used for psoriasis and psoriatic arthritis.…”

Section: Discussionmentioning

confidence: 97%

Treatment of recalcitrant erosive oral lichen planus and desquamative gingivitis with oral apremilast

AbuHilal

Walsh

Shear

2017

J Dermatol Case Rep

View full text Add to dashboard Cite

Background: Erosive oral lichen planus and desquamative gingivitis are uncommon but severe debilitating variants of oral lichen planus. Treatment of these presentations is difficult and challenging. Main observation:A 44-year-old woman was referred to the dermatology clinic with chronic painful lichen planus-related gingivitis and buccal erosions. She has failed multiple treatments including topical clobetasol and tacrolimus, intralesional corticosteroids and several systemic and immunosuppressive agents. Following completion of three months of treatment with oral apremilast at a dose of 30 mg twice daily, significant improvement was noted in her disease activity. Conclusion:Oral apremilast may be a safe and effective treatment for erosive oral lichen planus. (J Dermatol Case Rep. 2016; 10(3): 56-57) Treatment of recalcitrant erosive oral lichen planus and desquamative gingivitis with oral apremilast

show abstract

Section: Discussionmentioning

confidence: 97%

Treatment of recalcitrant erosive oral lichen planus and desquamative gingivitis with oral apremilast

AbuHilal

Walsh

Shear

2017

J Dermatol Case Rep

View full text Add to dashboard Cite

show abstract

“…It showed good clinical and safety data in an open-label pilot study in AD patients [55, 60–64], as well as in clinical trials for other inflammatory and dermatological conditions [61–63, 65], including AA (NCT02684123). Despite its broad activation, affecting many inflammatory cells (including neutrophils and peripheral blood mononuclear cells (PBMCs): monocytes, plasmacytoid DCs, T cells, and natural killer cells), the drug is well tolerated and requires minimal monitoring [57].…”

Section: Broad T Cell Antagonismmentioning

confidence: 99%

The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm

Renert‐Yuval

Guttman‐Yassky

2017

Adv Ther

View full text Add to dashboard Cite

Alopecia areata (AA), a prevalent inflammatory cause of hair loss, lacks FDA-approved therapeutics for extensive cases, which are associated with very poor rates of spontaneous hair regrowth and major psychological distress. Current treatments for severe cases include broad immune-suppressants, which are associated with significant adverse effects, precluding long-term use, with rapid hair loss following treatment termination. As a result of the extent of the disease in severe cases, topical contact sensitizers and intralesional treatments are of limited use. The pathogenesis of AA is not yet fully understood, but recent investigations of the immune activation in AA skin reveal Th1/IFN-γ, as well as Th2, PDE4, IL-23, and IL-9 upregulations. Tissue analyses of both animal models and human lesions following broad-acting and cytokine-specific therapeutics (such as JAK inhibitors and ustekinumab, respectively) provide another opportunity for important insights into the pathogenesis of AA. As reviewed in this paper, numerous novel therapeutics are undergoing clinical trials for AA, emphasizing the potential transformation of the clinical practice of AA, which is currently lacking. Dermatologists are already familiar with the revolution in disease management of psoriasis, stemming from better understanding of immune dysregulations, and atopic dermatitis will soon follow a similar path. In light of these recent developments, the therapeutic arena of AA treatments is finally getting more exciting. AA will join the lengthening list of dermatologic diseases with mechanism-targeted drugs, thus changing the face of AA.

show abstract

“…7 Paul et al carried out a pilot study showing that apremilast may be an effective agent for the treatment of lichen planus. 8 The results showed that 8 of 10 patients with biopsy-proven lichen planus demonstrated a 2-grade or higher improvement in the Physician Global Assesment following 12 weeks of therapy. Given that LPP is a follicular variant of lichen planus, we used apremilast in our cohort of patients with LPP refractory to currently used treatment modalities.…”

Section: Figuresmentioning

confidence: 97%

Apremilast for Lichen Planopilaris and Frontal Fibrosing Alopecia: A Case Series

Hadi¹,

Lebwohl²

2017

J of Skin

View full text Add to dashboard Cite

Importance: Lichen planopilaris and frontal fibrosing alopecia are characterized by scarring alopecia associated with pruritus, inflammation, and pain of affected areas. There is a paucity of data on treatment options for these disorders. The available management options are associated with significant adverse effects and poor efficacy. Objective: To explore apremilast as a treatment option for refractory lichen planopilaris and frontal fibrosing alopeciaDesign: This is a retrospective case series analyzing the outcomes of four patients with refractory lichen planopilaris or frontal fibrosing alopecia treated with apremilast.

show abstract

An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: A case series

Cited by 47 publications

References 10 publications

Treatment of recalcitrant erosive oral lichen planus and desquamative gingivitis with oral apremilast

Treatment of recalcitrant erosive oral lichen planus and desquamative gingivitis with oral apremilast

The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm

Apremilast for Lichen Planopilaris and Frontal Fibrosing Alopecia: A Case Series

Contact Info

Product

Resources

About